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Abstract 33 
Background: Diets high in n-3 long chain polyunsaturated fatty acids (LCPUFA) may 34 
modulate the development of IgE-mediated allergic disease and have been proposed as a 35 
possible allergy prevention strategy. The aim of this study was to determine whether n-3 36 
LCPUFA supplementation of pregnant women reduces IgE-mediated allergic disease in their 37 
children. 38 
Methods: Follow-up of children (n=706) at hereditary risk of allergic disease in the 39 
Docosahexaenoic Acid to Optimise Mother Infant Outcome randomised controlled trial.  The 40 
intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 41 
900 mg of n-3 LCPUFA daily) from 21 weeks’ gestation until birth; the control group 42 
(n=338) received matched vegetable oil capsules without n-3 LCPUFA.  The diagnosis of 43 
allergic disease was made during medical assessments at 1 and 3 years of age. 44 
Results: No differences were seen in the overall percentage of children with IgE-mediated 45 
allergic disease in the first 3 years of life between the n-3 LCPUFA and control groups 46 
(64/368 (17.3%) v 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58 to 1.06; P=0.11).  47 
Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group 48 
had eczema with sensitisation compared with 19.0% in the control group (adjusted relative 49 
risk 0.75; 95% CI 0.53 to 1.05; P=0.10).  50 
Conclusions: Overall n-3 LCPUFA supplementation during pregnancy did not significantly 51 
reduce IgE-associated allergic disease in the first three years of life.  Further studies should 52 
examine whether the non-significant reductions in IgE-associated allergies are of clinical and 53 
public health significance. 54 
  55 
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Introduction 70 
Changing dietary patterns have favoured increased intake of n-6 polyunsaturated fatty acids 71 
(PUFA) from linoleic acid (18:2, n-6) rich vegetable oils, especially since margarine and 72 
vegetable oils have became a common dietary staples over the past 40 years. This, together 73 
with an increase in consumption of meat-based products, has led to an increase of arachidonic 74 
acid (AA, 20:4, n-6) in tissues.  AA gives rise to eicosanoids such as prostaglandin E2 that 75 
can enhance the synthesis of T helper type 2 cytokines and immunoglobulin E (IgE) 76 
antibodies potentially leading to sensitisation to allergens.  However when diets are high in n-77 
3 long-chain (LC) PUFA (from fatty fish and fish oils) they are readily incorporated into 78 
cellular phospholipids and thereby displace AA and alter membrane composition and fluidity.  79 
This leads to a range of immunological effects, including reduction of prostaglandin E2 80 
synthesis (1, 2) providing a plausible mechanism by which diets high in n-3 LCPUFA may 81 
modulate the development of IgE-mediated allergic disease.   82 
 83 
In support of this biological mechanism, epidemiological studies have reported that increased 84 
maternal fish intake during pregnancy is associated with reduced atopic or allergic outcomes 85 
in children (3-7).  Furthermore, evidence from randomised controlled trials (RCTs) (8-11) 86 
involving fish oil supplementation of pregnant women have found beneficial effects on 87 
reduced allergen sensitisation and allergic disease outcomes in the offspring.  However 88 
previous RCTs have only reported allergic disease outcomes at 1 year (8, 9), 2 years (12) and 89 
16 years of age (10) and none have reported outcomes between 2 and 16 years of age. 90 
 91 
Our study was specifically designed to assess the effect of n-3 LCPUFA supplementation, 92 
predominantly as DHA, in pregnancy on the cumulative incidence of IgE-mediated allergic 93 
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disease in the first 3 years of life.  Outcome data focussing on eczema and food allergy over 94 
the first year of life have been previously published (11).  95 
96 
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Methods 97 
Subjects and study design 98 
The present study is an allergy follow-up of a subset of children whose mothers were 99 
participants in the Docosahexaenoic Acid (DHA) to Optimise Mother Infant Outcome 100 
(DOMInO) Trial (13). This subset of children all had a mother, father or sibling with a 101 
history of medically diagnosed allergic disease (asthma, allergic rhinitis, eczema) and they 102 
were enrolled at either of the two study centres in Adelaide, Australia. Full details of entry 103 
into this allergy follow-up study have been previously published (11). Written informed 104 
consent was sought before birth and included consent for their offspring to participate in both 105 
the 1 and 3 year of age allergy follow-up assessments. Approval for this study was granted by 106 
the Human Research Ethics Committees of each centre, Women’s and Children’s Hospital, 107 
Adelaide and Flinders Medical Centre, Adelaide. This allergy follow-up study was registered 108 
at www.anzctr.org.au as ACTRN12610000735055. The Docosahexaenoic Acid to Optimise 109 
Mother Infant Outcome (DOMInO) trial was registered at www.anzctr.org.au as 110 
ACTRN12605000569606. 111 
 112 
The dietary treatments for the DOMInO trial have been previously described (13). Briefly, 113 
women allocated to the n-3 LCPUFA group were asked to consume three 500 mg capsules of 114 
fish oil concentrate, providing 800 mg of DHA and 100 mg of eicosapentaenoic acid (EPA); 115 
women in the control group were asked to take three 500 mg vegetable oil capsules without 116 
n-3 LCPUFA daily. This was a double-blinded study; all capsules were similar in size, shape 117 
and colour.  Women took capsules from 21 weeks’ gestation until delivery. 118 
 119 
Early childhood allergic disease outcome assessments and definitions 120 
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The primary outcome was diagnosis of IgE-associated allergic disease (eczema, asthma, 121 
allergic rhinitis or food allergy) at 1 or 3 years of age.  Participating children attended a 122 
medical review appointment at 1 and 3 years of age, conducted by one of six medical 123 
practitioners (who made the allergic disease diagnosis for a period covering the previous 12 124 
months by taking a structured history and doing a standardised clinical examination) and one 125 
of six experienced research nurses (who performed skin prick testing).  All were blinded to 126 
treatment group allocation and had quality assurance reviews every six months with one of 127 
the investigators (DJP). Data were also collected on possible confounding variables, 128 
including details of number of other children in the home, use of house dust mite covers for 129 
mattresses and pillows, presence of a cat as a pet and household smoking exposure.  130 
 131 
Sensitisation was defined as a positive skin prick test (wheal ≥3mm above negative control) 132 
to at least one of the allergens assessed.  At 1 year of age, the food allergens tested were 133 
whole hens’ egg, cows’ milk, wheat, tuna and peanut, and the aeroallergens tested were 134 
ryegrass pollen, olive tree pollen, Alternaria tenuis, cat hair and house dust mite 135 
(Dermatophagoides pteronyssinus).  At 3 years of age, the same allergens were tested with 136 
the addition of two foods (cashew nut and sesame seed) and one aeroallergen (house dust 137 
mite, Dermatophagoides farinae). The cow’s milk allergen extract became unavailable from 138 
the supplier for an extended period during the 3 year assessments and consequently was 139 
excluded from the definition of sensitisation at 3 years.  140 
 141 
Eczema was defined as the presence of eczema (criteria according to (14)) on medical review 142 
or a history of an itchy rash distributed to the facial, flexural, or extensor surface of the skin 143 
that had followed a fluctuating or chronic course.  We defined IgE-associated eczema or 144 
atopic eczema as eczema with sensitisation to at least one of the allergens assessed. IgE-145 
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associated food allergy was defined as a history within the of immediate (within 60 minutes) 146 
skin rash (hives, rash, or swelling) with or without respiratory symptoms (cough, wheeze, 147 
stridor), gastrointestinal symptoms (abdominal pain, vomiting, loose stools), or 148 
cardiovascular symptoms (collapse) following ingestion of a food and sensitisation to the 149 
implicated food. Asthma was defined a history of 3 or more episodes of wheeze with the 150 
episodes less than 6 weeks apart and/or daily use of asthma medication.  Allergic rhinitis was 151 
defined as a history of sneezing, or a runny, or blocked nose accompanied by itchy-watery 152 
eyes when there have not been symptoms to suggest an upper respiratory tract infection.  IgE-153 
associated asthma/allergic rhinitis was defined as asthma/allergic rhinitis along with 154 
sensitisation to at least one of the aeroallergens tested.  155 
 156 
Statistical methods 157 
With >328 children per treatment group we would be able to detect an absolute reduction of 158 
10% (relative reduction of 33%) in the cumulative incidence of IgE-mediated allergic disease 159 
from 30% to 20% with >80% power (α = 0.05) over the first 3 years of life.  Such a reduction 160 
was realistic based on the pilot data from Dunstan et al (8).  161 
 162 
All analyses were performed according to the intention to treat principle.  Multiple 163 
imputation was used to deal with missing data, with 50 complete datasets imputed for 164 
analysis.  Overall the missing at random assumption of the multiple imputation approach 165 
appeared reasonable for these data. Binary outcomes were analysed using log binomial 166 
regression models, with treatment effects expressed as relative risks.  Rare binary outcomes 167 
were compared between groups using Fisher’s exact tests on the original (unimputed) data.  168 
Negative binomial regression models were used to analyse count outcomes, with the effect of 169 
treatment expressed as a ratio of means. Both unadjusted and adjusted analyses were 170 
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performed, with adjustment for the stratification variables of centre and parity as well as the 171 
pre-specified baseline variables of infant sex and maternal history of allergic disease.  The 172 
adjusted analyses were considered to be the primary analyses.  Potential confounding 173 
variables (environmental characteristics measured after randomization) that may influence 174 
allergic disease outcomes were compared between groups using Mann Whitney and chi 175 
square tests.  Statistical significance was assessed at the two sided P<0.05 level.  All analyses 176 
were performed using SAS version 9.3.  177 
 178 
179 
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Results 180 
The allergy follow-up trial profile is shown in Figure 1.  Enrolment began on 20th March 181 
2006 and ended on 8th May 2008, with a total of 706 infants recruited into the study.  Data 182 
collection for the medical assessments at 3 years of age was completed on 1st September 183 
2011.  638/706 (90.4%) children attended a medical review at 3 years of age with 587/706 184 
(83.1%) of children having skin prick testing to determine their sensitisation status.  185 
 186 
Demographic and family characteristics 187 
The participants consisted of 337/706 (47.7%) males and 281/706 (39.8%) were the first born 188 
(parity zero).  Mean maternal age at trial entry was 29.6 years (SD 5.7 years) and 92/706 189 
(13.0%) of the participating mothers smoked during pregnancy.  All participants had at least 190 
one first degree relative with a history of medically diagnosed allergic disease; 656/706 191 
(92.9%) had a least one parent and 206/706 (29.2%) had both parents with a history of 192 
allergic disease.  Other baseline demographic characteristics of the trial participants and their 193 
families have been previously reported (11).  Early childhood (0-3 years) home 194 
environmental characteristics are shown in Table 1; there were no statistically significant 195 
differences between the groups.  196 
 197 
Early Childhood Allergic Disease Outcomes  198 
In the n-3 LCPUFA intervention group 17.3% of children were diagnosed with IgE-mediated 199 
allergic disease (asthma, allergic rhinitis, eczema and/or food allergy) in the first 3 years of 200 
life compared with 22.6% in the control group (adjusted relative risk 0.78; 95% CI 0.58 to 201 
1.06; P=0.11; Table 2).  As expected, the most common IgE-mediated allergic disease in the 202 
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first 3 years of life was eczema with sensitisation, affecting a total of 115/706 (16.3%) of the 203 
participating children.  There was a lower, but not statistically significant, incidence of 204 
eczema with sensitisation in the n-3 LCPUFA group (13.8% vs 19.0% control group, adjusted 205 
relative risk 0.75; 95% CI 0.53 to 1.05; P=0.10; Table 2).  Overall 4.6% of the children were 206 
diagnosed with at least one IgE-mediated food allergy through to 3 years of age and egg 207 
allergy was the most common, affecting 2.8% of the children.  There were no differences 208 
between the n-3 LCPUFA and control groups in the percentage of children diagnosed with 209 
food allergy or respiratory allergic diseases (asthma, allergic rhinitis) with sensitisation 210 
through to 3 years of age (Table 2).  The percentage of children diagnosed with allergic 211 
disease without sensitisation (non IgE-mediated) did not differ between groups at either time 212 
point (Tables 2 and 3).   213 
 214 
Table 3 reports the allergic disease outcomes at 3 years of age and demonstrates that there 215 
were no differences between the n-3 LCPUFA and control groups.  The percentage of 216 
children diagnosed with  eczema with sensitisation at 3 years of age was 13.0% and higher 217 
than that reported at 1 year of age (9.2% (11)).  Of the 92 children diagnosed with IgE-218 
associated eczema at 3 years of age, 54% were new cases (25 in each group) who did not 219 
have IgE-associated eczema at 1 year of age.   220 
 221 
There was no difference between the groups in sensitisation to at least one allergen at 1 or 3 222 
years of age, with 29.4% of children in the n-3 LCPUFA group sensitised compared with 223 
35.2% in the control group (adjusted relative risk 0.85; 95% CI 0.68 to 1.06; P=0.14; Table 224 
2).  At 3 years of age, 24.6% of children in the n-3 LCPUFA group compared with 26.1% in 225 
the control group were sensitised to at least one allergen (adjusted relative risk 0.96; 95% CI 226 
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0.74 to 1.25; P=0.76; Table 4). Alternaria Tenius (grass mould) (total of 7.8%), ryegrass 227 
pollen (total of 7.1%) and D. Pteronyssinus (total of 6.8%) were the most common allergens 228 
that children were sensitized to at 3 years (Table 4).  Despite no differences in cat ownership 229 
between the groups in the first 3 years of life (Table 1), 6.8% of children in the n-3 LCPUFA 230 
group compared to 3.4% in the control group were sensitised to cat at 3 years of age, however 231 
this difference did not reach statistical significance (adjusted relative risk = 1.95; 95% CI 232 
0.98 to 3.89; P=0.06; Table 4).  Figure 2 illustrates the changing profile of sensitisation status 233 
from predominately food allergen sensitisation at 1 year of age to increased aeroallergen 234 
sensitisation at 3 years of age.  Egg sensitisation was found in a total of 86/706 (12.2%) of the 235 
children at 1 year of age but only 27/706 (3.8%) at 3 years of age.  236 
  237 
238 
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Discussion 239 
This study is the largest randomised controlled trial of fish oil supplementation during 240 
pregnancy and was designed to resolve uncertainties surrounding the use of n-3 LCPUFA 241 
supplementation in pregnancy as an allergic disease preventative strategy for children with 242 
hereditary risk.  Overall fish oil supplementation in pregnancy did not significantly reduce the 243 
cumulative incidence of IgE-associated allergic disease over the first 3 years of life.  Our 244 
study was powered to detect a 33% relative reduction in allergic disease and it is therefore not 245 
surprising that the differences noted did not reach statistical significance.  The non-significant 246 
risk reductions of up to 22% may still be of public health significance as the burden and cost 247 
of allergic disease on affected families is high and fish oil intervention is safe and relatively 248 
cheap.  249 
 250 
The lower incidence of IgE-associated eczema observed at 1 year of age in the n-3 LCPUFA 251 
group did not persist at 3 years of age.  As more than half of the children diagnosed with 252 
eczema with sensitisation at 3 years of age did not have this diagnosis at 1 year of age, it is 253 
interesting to question whether these new cases could have been reduced if the n-3 LCPUFA 254 
supplementation had continued beyond pregnancy during early childhood.  A recent postnatal 255 
(0-6 months of age) n-3 LCPUFA supplementation trial (n= 420) (15) found no overall effect 256 
on allergic disease outcomes at 1 year of age, but there was a significant reduction in eczema 257 
diagnosis in those infants who had higher n-3 LCPUFA levels at 6 months of age.  This may 258 
be an important influencing factor as Furuhjelm et al (12) (n-3 LCPUFA supplementation 259 
during pregnancy and first 3.5 months of lactation) also found higher maternal and infant 260 
proportions of DHA and EPA in plasma phospholipids were associated with lower prevalence 261 
of IgE-associated allergic disease in a dose-dependent manner.  Interestingly compared with 262 
our study, other studies have used higher doses of n-3 LCPUFA that have ranged from 263 
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2700mg/day (10,12) to 3700mg/day (8) and it may be that higher n-3 LCPUFA doses are 264 
needed to result in reduced allergic disease outcomes.  Dose, timing and duration of n-3 265 
LCPUFA supplementation are important considerations and worthy of further investigation.  266 
A limitation of our study was that we have not taken blood samples from the children and 267 
hence cannot report on their n-3 LCPUFA plasma phospholipids levels at 1 or 3 years of age. 268 
 269 
The pattern of allergic disease is known to differ with age, with the greatest incidence of food 270 
allergy and atopic dermatitis/eczema being in the first few years of life, while asthma and 271 
allergic rhinitis continue to rise until adulthood (16).  Similarly the changing sensitisation 272 
pattern was as expected; the incidence of food allergen sensitisation decreased and the 273 
aeroallergen sensitisation increased between 1 to 3 years of age (17, 18).  Specifically, the 274 
frequency of egg sensitisation significantly reduced and the significant reduction in egg 275 
sensitisation at 1 year of age with n-3 LCPUFA treatment (9.3% vs 15.4%; adjusted relative 276 
risk 0.62; 95% CI 0.41 to 0.93; P=0.02) (11) disappeared by 3 years of age.  One could 277 
question whether the timing of various allergen exposures during the first few years of life 278 
and the corresponding timing of the n-3 LCPUFA supplementation may influence the pattern 279 
of sensitisation.   280 
 281 
Conclusion 282 
Overall n-3 LCPUFA supplementation during pregnancy did not result in a significant 283 
reduction in IgE-associated allergic disease in the first three years of life to the magnitude 284 
originally predicted.  Collectively, results from this and other n-3 LCPUFA supplementation 285 
RCTs suggest that the dose, timing and duration of n-3 LCPUFA supplementation may 286 
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influence sensitisation and allergic disease outcomes.  Clearly further follow up studies are 287 
required to definitively determine whether there is benefit in n-3 LCPUFA supplementation 288 
as an allergy prevention strategy.  289 
 290 
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